logo
Pantex completes first B61-13 nuclear bomb unit after B61-12 finale

Pantex completes first B61-13 nuclear bomb unit after B61-12 finale

Yahoo22-05-2025

Just four months after finalizing production on the B61-12, the Pantex Plant has completed the first production unit (FPU) of the B61-13 nuclear gravity bomb, the National Nuclear Security Administration (NNSA) announced this week.
The milestone, achieved in partnership with PanTeXas Deterrence LLC, marks the latest advance in the United States' nuclear modernization efforts.
"In this geopolitical environment, the Nuclear Security Enterprise performs work that saves the world every day,' said Jason Armstrong, manager of the NNSA's Pantex Field Office. 'Through meticulous planning, strong partnerships, and exceptional execution, Pantex and the rest of the enterprise continue to fulfill our mission of protecting America and its allies to help ensure global security.'
The B61 nuclear bomb has been in service since 1968. Over the past decade, it underwent an extensive Life Extension Program (LEP) to replace aging components and extend its service life by at least 20 years. That effort culminated in the B61-12, the largest weapons modification ever executed by the Nuclear Security Enterprise (NSE).
Now, the B61-13 builds on that groundwork with updated features and streamlined production processes.
'The FPU is just the start,' said Kelly Beierschmitt, president and general manager of Pantex. 'With every unit comes progress and an enhanced ability for the NSE to deliver if or when the need arises. We do this work to protect our nation, our families, and our communities.'
According to Pantex Program Manager Taylor Massey, the B61-13 was developed using a phased approach, allowing engineers to move quickly from design to testing and assembly by leveraging the established design of the B61-12.
'Modernization programs typically follow a detailed product realization process,' Massey said. 'We tailored our approach to accelerate readiness, developing procedures, tooling and testers that allowed us to produce an FPU within a year.'
Six NNSA sites contributed to the development and production of the B61-13: Sandia National Laboratories, Los Alamos National Laboratory, Kansas City National Security Campus, Y-12 National Security Complex, Savannah River Site, and Pantex.
The program reached full authorization in March and is scheduled to enter full-scale production this summer, with completion targeted for fiscal year 2027.
'There are over 200 parts involved in a single unit of the B61-13,' said Mickey Brown, B61 technical lead at Pantex. 'Almost all of those parts are produced by external partners within the NSE, then shipped to us for final assembly.'
Massey added that the team's ability to meet aggressive timelines underscores Pantex's capacity for agility and performance.
'Following NNSA guidance to be more agile and flexible has shown we can meet designated production targets,' he said. 'That flexibility extends across everything from engineering and safety evaluations to the technicians on the floor meeting demanding schedules.'
This achievement, Massey said, demonstrates that Pantex remains at the forefront of the nation's nuclear production efforts, driven by a skilled and collaborative workforce dedicated to national defense.
This article originally appeared on Amarillo Globe-News: Pantex finishes first B61-13 nuclear gravity bomb, begins new production phase

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Save $269 on our favorite open-back headphones and experience music in a whole new way
Save $269 on our favorite open-back headphones and experience music in a whole new way

Digital Trends

time10 hours ago

  • Digital Trends

Save $269 on our favorite open-back headphones and experience music in a whole new way

We may have recently given Sennheiser a bit of flack for launching earbuds that look like AirPods (which is a pretty common thing to do) but that doesn't mean they don't have audiophile-grade offerings. The open-back Sennheiser HD 660S2 are a pretty good example of that. They probably flew under your radar, though, because of their standard price in excess of $600. They're typically rank No. 2 by cost in our list of the best headphones, right after the $1,000+ Dali IO-12. But, right now, with this 40% discount, they're actually cheaper than Apple's AirPods Max. So, if you want to check out audiophile headphones for $411 (that's $269 off their usual price of $680) be sure to tap the button below. Or, keep reading for our take. Why you should buy the Sennheiser HD 660S2 As counterintuitive as it may sound, open-back headphones can absolutely provide a premium sound. The Sennheiser HD 660S2 act as a sort of antonym to the shut-out-the-world ethic of the Sony WH-1000XM6 and not at all in a bad way. These headphones have plush ear cushions with a hefty amount of clamp on the head and an overall minimalist design, though you won't always think of it that way as you peer into the guts of the headphones that their closed-back cousins keep hidden. Our Sennheiser HD 660S2 review calls their sound 'effortless' and says, 'It just springs forth and gently bathes you in its detail, instead of pummeling you, which I now recognize as a possible side effect of closed-back headphones.' Be sure to give the review a read through to see how to get the full audiophile experience from your new HD 660S2s, as well as to get insights on the full extent of how open-back headphones can transform your music listening experience. These audiophile headphones aren't typically down to $411. It's an incredible discount of $269 off of the usual $680 price, making them way more competitive than usual. So, if you want them, don't wait for this deal to go away. However, if you want something else, you should be sure to check out the other best headphone deals going on right now.

Simulations Plus Releases ADMET Predictor® 13
Simulations Plus Releases ADMET Predictor® 13

Yahoo

time17 hours ago

  • Yahoo

Simulations Plus Releases ADMET Predictor® 13

Expanded functionality and advanced AI/ML capabilities deliver faster, more accurate predictions and streamline enterprise deployment RESEARCH TRIANGLE PARK, N.C., June 05, 2025--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13 features advancements in three main areas: First-to-invent advantage: clients can harness enhanced high-throughput PBPK (HT-PBPK) simulations—powered by GastroPlus®—combined with the upgraded AI-driven drug design (AIDD) engine to enable faster, smarter decision-making at the intersection of chemistry and pharmacokinetics. Elevated predictive power: ADMET Predictor 13 offers an expanded suite of next-gen ADMET models, built with updated AI science and premium datasets, which boost accuracy across key endpoints and reinforce scientific rigor and validation. Enterprise-ready automation: with extended APIs, Python scripting support, and IT-friendly deployment capabilities, ADMET Predictor 13 delivers the automation and scalability required by today's data-centric R&D teams. "ADMET Predictor has long been the standard for discovery modeling platforms in the pharmaceutical space," said David Miller, Vice President of Cheminformatics of Simulations Plus. "Before artificial intelligence and machine learning became industry buzzwords, ADMET Predictor was already leveraging these technologies to help our clients design and optimize new compounds. By tightly integrating mechanistic simulation with AI/ML and wrapping it in a powerful, customizable software platform that can be seamlessly deployed into existing workflows, we are now making predictions more accurate and easier to access for our clients around the world." Learn more about ADMET Predictor 13 or request a demo. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "will", "can", "believe", "expect," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward looking statements contained in this press release include, but are not limited to, statements about expectations for the second half of 2025 and anticipated projections for fiscal year 2025. Factors that could cause or contribute to such differences include, but are not limited to: our ability to integrate our ALI and MC business units, our ability to meet our stated guidance, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. View source version on Contacts Financial Profiles Lisa Fortuna310-622-8251slp@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Simulations Plus Releases ADMET Predictor® 13
Simulations Plus Releases ADMET Predictor® 13

Business Wire

time17 hours ago

  • Business Wire

Simulations Plus Releases ADMET Predictor® 13

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ('Simulations Plus'), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13 features advancements in three main areas: First-to-invent advantage: clients can harness enhanced high-throughput PBPK (HT-PBPK) simulations—powered by GastroPlus®—combined with the upgraded AI-driven drug design (AIDD) engine to enable faster, smarter decision-making at the intersection of chemistry and pharmacokinetics. Elevated predictive power: ADMET Predictor 13 offers an expanded suite of next-gen ADMET models, built with updated AI science and premium datasets, which boost accuracy across key endpoints and reinforce scientific rigor and validation. Enterprise-ready automation: with extended APIs, Python scripting support, and IT-friendly deployment capabilities, ADMET Predictor 13 delivers the automation and scalability required by today's data-centric R&D teams. 'ADMET Predictor has long been the standard for discovery modeling platforms in the pharmaceutical space,' said David Miller, Vice President of Cheminformatics of Simulations Plus. 'Before artificial intelligence and machine learning became industry buzzwords, ADMET Predictor was already leveraging these technologies to help our clients design and optimize new compounds. By tightly integrating mechanistic simulation with AI/ML and wrapping it in a powerful, customizable software platform that can be seamlessly deployed into existing workflows, we are now making predictions more accurate and easier to access for our clients around the world.' Learn more about ADMET Predictor 13 or request a demo. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like 'believe,' 'will', 'can', 'believe', 'expect,' 'anticipate' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward looking statements contained in this press release include, but are not limited to, statements about expectations for the second half of 2025 and anticipated projections for fiscal year 2025. Factors that could cause or contribute to such differences include, but are not limited to: our ability to integrate our ALI and MC business units, our ability to meet our stated guidance, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store